A new study, known as GLP-1 (for peptide-1 receptor agonists such as glucagon), demonstrates the effectiveness of a drug made from a toxin hormone, the first of its kind to be used to treat type 2 diabetes, and a series of additional findings involving drug-induced toxins.
After doctors noticed that rats and humans were losing weight by taking diabetes medication, they began using it in the science of obesity. It is approved by the Food and Drug Administration. It is called semaglutide and is marketed under the name Vigovi. Lizard venom.
Doctors and researchers say a new treatment — the injection once a week by Danish drugmaker Novo Nordisk – has hired many diabetics and obese scientists as consultants — ready to safely help many overweight people who pose a threat to health.
According to Vauxhall, Michael Crash, a researcher on diabetes and obesity at the National Institutes of Health, says:
